Financial Performance - The company's operating revenue for 2020 was ¥1,022,229,215.88, representing a 54.36% increase compared to ¥662,230,933.19 in 2019[31]. - The net profit attributable to shareholders for 2020 was ¥184,207,681.24, which is a 21.13% increase from ¥152,068,782.22 in 2019[31]. - The net cash flow from operating activities reached ¥271,505,518.45, showing a significant increase of 113.71% compared to ¥127,044,730.52 in 2019[31]. - The total assets at the end of 2020 amounted to ¥2,425,289,638.00, a 135.66% increase from ¥1,029,138,127.42 at the end of 2019[31]. - The basic earnings per share for 2020 was ¥1.29, up 21.70% from ¥1.06 in 2019[31]. - The company reported a quarterly revenue of ¥296,792,692.89 in Q4 2020, contributing to a total annual revenue growth[34]. - The net profit attributable to shareholders in Q4 2020 was ¥41,868,126.57, indicating a strong performance in the last quarter[34]. - The company's net profit after deducting non-recurring gains and losses for 2020 was ¥173,573,289.18, a 26.77% increase from ¥136,914,624.38 in 2019[31]. - The weighted average return on net assets for 2020 was 21.76%, slightly down from 22.94% in 2019[31]. - The gross profit margin for the company was 45.79% in 2020[49]. - The company's total revenue for 2020 reached approximately ¥1.02 billion, representing a year-on-year increase of 54.36% compared to ¥662.23 million in 2019[79]. Cash Dividend and Profit Distribution - The company reported a profit distribution plan to distribute a cash dividend of 1 RMB per 10 shares to all shareholders, totaling 153,615,151 RMB[8]. - The cash dividend for 2020 accounted for 8.34% of the net profit attributable to ordinary shareholders, which was RMB 184,207,681.24[143]. - The cash dividend distribution policy complies with the company's articles of association and relevant regulations[138]. - The company has maintained a clear and transparent decision-making process for profit distribution, ensuring the protection of minority shareholders' rights[138]. - The company distributed cash dividends of RMB 1.00 per 10 shares, totaling RMB 15,361,515.10, which represents 100% of the distributable profit[139]. - The cash dividend distribution for 2019 was RMB 21,718,425.15, which was 14.28% of the net profit[143]. - The cash dividend distribution for 2018 was RMB 22,000,000.20, which was 16.50% of the net profit[143]. Research and Development - The company has a diverse portfolio of products, including small molecule drugs and pharmaceutical intermediates, which are crucial for its growth strategy[16]. - The company is focused on expanding its market presence and enhancing its research and development capabilities for new products[16]. - The company is actively involved in the development of innovative drugs and aims to improve the success rate of new drug research[16]. - The company is leveraging high-throughput screening and virtual screening technologies to enhance its drug discovery efforts[16]. - The company has established a diverse library of drug molecular building blocks, enhancing its capabilities in drug discovery and development[44]. - The company has constructed a fragment library containing approximately 8,000 compounds, including a unique medium-sized compound library, enhancing the diversity and reliability of lead compounds[68]. - The DNA-encoded library (DEL) has expanded to 15 billion compounds, with over 100 sub-libraries, significantly improving the success rate of screening[68]. - The company completed over 50 new target screenings in 2020, covering key areas such as kinases, protein-protein interactions, and epigenetics, among others[68]. - The company has designed over 11,000 unique molecular building blocks and developed more than 2,500 distinctive molecular blocks in 2020[63]. - The company has established a high-quality CDMO service platform to provide efficient and high-quality process development and production services[64]. Market and Competitive Landscape - The company faces risks including industry policy changes, intensified market competition, and potential declines in gross margin due to customer project progress[8]. - The company maintains strong partnerships with major pharmaceutical and biotechnology firms, with over 70% of sales coming from international markets[52]. - The global pharmaceutical R&D spending is projected to reach $203.9 billion by 2024, indicating a growing market for the company's services[49]. - The company’s sales growth is closely tied to the progress of clients' drug development projects, which may limit revenue growth if projects are delayed[129]. - The company faces risks from market competition, particularly from new entrants in the pharmaceutical industry, and plans to maintain its competitive edge through continuous R&D investment[128]. Operational Efficiency and Investments - The company has implemented new strategies to improve operational efficiency, aiming for a 15% reduction in production costs by the end of the fiscal year[164]. - The company plans to invest 200 million RMB in technology upgrades over the next year to enhance production capabilities[166]. - The company has committed to maintaining a dividend payout ratio of 30% of net profits, ensuring returns to shareholders[167]. - The company has committed to an investment project for the development of innovative drug molecular building blocks, with a total investment commitment of 18,272.4 million yuan and a progress of 79.04%[107]. - The construction of the R&D center in Nanjing has a total investment commitment of 30,300 million yuan, with a target completion date of December 31, 2023[107]. Risk Management and Compliance - The company emphasizes environmental protection and safety in production, continuously investing in facilities to ensure compliance and minimize risks[129]. - The company has established a comprehensive quality management system to mitigate risks related to product quality control[132]. - The company monitors exchange rate fluctuations closely, as a significant portion of its revenue comes from international sales, and employs hedging strategies to manage this risk[133]. - The company has not experienced any significant changes in the measurement attributes of its major assets during the reporting period[99]. - The company has not sold any major assets or equity during the reporting period, indicating stability in its asset management[119].

Financial Performance - Operating revenue for the reporting period was ¥265,984,585.96, representing a year-on-year growth of 53.11%[9] - Net profit attributable to shareholders was ¥55,003,356.65, up 14.21% from the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥52,692,174.88, an increase of 15.82% year-on-year[9] - Net profit increased by 40.54% to ¥418,149,216.39, driven by higher overall profitability[25] - Total revenue for the third quarter reached ¥265,984,585.96, a significant increase of 53.2% compared to ¥173,722,435.32 in the same period last year[57] - Net profit for the quarter was ¥55,051,191.25, compared to ¥48,163,566.91 in the previous year, representing an increase of 14.1%[63] - The company's total operating revenue for the current period reached ¥320,708,986.38, a significant increase of 64.0% compared to ¥195,443,920.69 in the previous period[67] - The net profit for the current period was ¥50,836,593.41, representing a 26.5% increase from ¥40,239,454.10 in the previous period[70] - The net profit attributable to the parent company was ¥126,931,133.61, up 20.1% from ¥105,638,624.44 in the same period last year[86] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,357,309,792.70, an increase of 31.89% compared to the end of the previous year[9] - Cash and cash equivalents increased by 113.92% to ¥349,924,939.75, driven by expanded sales and improved collection[25] - Inventory rose by 67.31% to ¥346,194,634.53 due to increased sales orders and higher stock levels[25] - The total liabilities increased to CNY 456,659,549.93 from CNY 288,267,845.67, which is an increase of about 59%[47] - The company's equity attributable to shareholders reached CNY 900,649,798.98, up from CNY 740,866,683.70, representing an increase of approximately 22%[50] - Current liabilities rose to ¥466,276,475.18, up from ¥273,021,422.76, indicating a 70.9% increase[57] - The company's total equity reached ¥885,732,018.89, compared to ¥742,747,631.27, reflecting an increase of 19.2%[57] Cash Flow - The net cash flow from operating activities was ¥52,181,972.45, a significant increase of 113.44% compared to the previous year[9] - Cash received from sales increased by 77.25% to ¥750,054,105.21, indicating improved cash flow from operations[28] - The company achieved a net cash inflow from operating activities of ¥792,333,130.39, compared to ¥434,227,238.92 in the previous year, reflecting improved operational efficiency[90] - Cash inflow from sales of goods and services reached 774,730,529.06 CNY, compared to 390,499,224.00 CNY in the same period last year, indicating a growth of about 98%[96] - The net cash flow from investing activities was -133,068.75 CNY, a significant improvement from -275,005,154.41 CNY in the previous period[96] Expenses - Operating costs surged by 84.10% to ¥392,473,509.24, reflecting the rise in sales revenue[28] - Management expenses increased by 90.39% to ¥87,546,939.14, primarily due to the recognition of stock incentive plan costs[28] - Research and development expenses were ¥18,872,308.63, slightly down from ¥20,343,873.60, a decrease of 7.2%[60] - Research and development expenses decreased to ¥12,780,884.67 from ¥17,197,490.24, indicating a reduction of 25.5%[67] - The company reported a financial expense of ¥9,701,902.05, compared to a financial income of -¥5,607,384.92 in the previous year[60] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,572[13] - The largest shareholder, Yang Minmin, holds 21.89% of the shares, totaling 31,774,630 shares[13] - Basic earnings per share for the reporting period were ¥0.3795, reflecting a growth of 12.68% year-on-year[9] - Basic and diluted earnings per share for the current period were both ¥0.3795, compared to ¥0.3368 in the previous period[66] - Basic and diluted earnings per share increased to ¥0.9822 from ¥0.8200, reflecting a growth of 19.7%[81] Government Support - The company received government subsidies amounting to ¥7,094,702.22 during the reporting period[12] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[74] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[84]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥459,451,937.03, representing a 58.17% increase compared to ¥290,478,611.12 in the same period last year[24]. - The net profit attributable to shareholders was ¥87,336,198.02, up 26.08% from ¥69,267,874.80 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was ¥81,916,220.11, reflecting a 25.41% increase from ¥65,316,768.31 in the previous year[24]. - The net cash flow from operating activities surged by 388.81% to ¥119,502,252.63, compared to ¥24,447,606.12 in the same period last year[24]. - Basic earnings per share increased by 25.00% to ¥0.60, up from ¥0.48 in the previous year[24]. - Total assets at the end of the reporting period reached ¥1,313,494,531.53, a 27.63% increase from ¥1,029,138,127.42 at the end of the previous year[24]. - The net assets attributable to shareholders amounted to ¥828,784,214.59, which is an 11.87% increase from ¥740,866,683.70 at the end of the previous year[24]. - The comprehensive gross margin for the first half of 2020 was 45.06%, down from 62.12% in 2017, indicating a potential risk of margin compression as the business scales[99]. - The company’s revenue and profit have shown continuous growth, driven by market demand and innovative product strategies[43]. Business Strategy and Operations - The company is a global leader in innovative chemical products and services for drug research and development, focusing on the design, synthesis, and sales of drug molecular building blocks and key intermediates[35]. - The company has established a library of tens of thousands of novel drug molecular building blocks, significantly improving the efficiency and success rate of clients' drug development[35]. - The main products include drug molecular building blocks ranging from laboratory-level to ton-level, categorized into various chemical structures such as aromatic heterocycles and saturated cyclic compounds[35]. - The company provides drug molecular building blocks for various stages of drug development, including preclinical and clinical phases, with a focus on large-scale production for clinical trials[37]. - The company utilizes its drug molecular building block library to offer R&D outsourcing and process development services, helping clients accelerate their drug development progress[39]. - The business model is centered around customer needs, with a complete procurement, R&D, production, testing, and sales system to enhance the efficiency and success rate of clients' new drug projects[39]. - The company has access to multiple authoritative databases for research and analysis, enabling it to design and synthesize drug molecular building blocks for the latest pharmaceutical projects[39]. - Clients often purchase hundreds to thousands of drug molecular building blocks at once to enrich their compound libraries, increasing the chances of successful screening[39]. - The company aims to expand its drug molecular building block library continuously, accumulating extensive synthesis experience in the process[39]. - The company has developed key drug discovery technology platforms, including fragment-based drug discovery (FBDD) and DNA-encoded library (DEL) technology, to enhance clients' early drug discovery capabilities[35]. - The company plans to focus on the small molecule drug sector, enhancing R&D investment across all stages of drug development[61]. Market Overview - The global pharmaceutical expenditure reached $1.2 trillion in 2018, with a year-on-year growth of approximately $100 billion, representing a 9% increase[46]. - By 2023, global pharmaceutical spending is projected to exceed $1.5 trillion, with emerging markets like China expected to reach $355.5 billion to $385.8 billion[46]. - The Chinese pharmaceutical market is the second largest globally, with expenditures reaching $137 billion in 2018, and is expected to grow at a compound annual growth rate (CAGR) of 3-6% to reach between $158.8 billion and $183.3 billion by 2023[46]. - The global drug research and development (R&D) spending was $165.1 billion in 2017, with projections to reach $203.9 billion by 2024, indicating a stable growth trend[46]. - The market for drug molecular building blocks is estimated to reach $61.2 billion by 2024, with 30% of global R&D spending allocated to the purchase and outsourcing of these building blocks[46]. Risks and Challenges - The company faces risks including slowing performance growth and declining gross margins, which investors should be aware of[7]. - The gross profit margin for kilogram-level products decreased by 9.66% to 37.85% despite a revenue increase of 76.75%[66]. - The company plans to expand sales channels and enhance customer relationships to mitigate risks associated with potential slowdowns in drug development investments by clients[96]. - The company has faced risks related to environmental and safety production, with ongoing investments in environmental protection and safety measures to mitigate these risks[99]. Research and Development - Research and development expenses amounted to 38.70 million yuan, reflecting a 30.09% increase, driven by the company's commitment to technological innovation[63]. - The company designed over 5,000 unique molecular building blocks and developed nearly 1,000 distinctive molecular building blocks in the first half of 2020[61]. - The company completed the production of over 200 different series of kilogram to ton-level molecular building blocks in the first half of 2020[61]. - The company applied for 19 patents in China and 2 PCT patents, receiving 13 patent grants in the first half of 2020[61]. Financial Position - Intangible assets increased by 35.04% due to the acquisition of land by a subsidiary, while cash and cash equivalents rose by 119.18% as a result of expanded sales and improved collection[50]. - Accounts receivable increased by 29.57%, reflecting the growth in sales volume[50]. - Cash and cash equivalents increased significantly to RMB 418,527,698.38 from RMB 163,576,155.41, marking a growth of approximately 156.5%[188]. - Total liabilities increased to ¥484,757,707.75, up from ¥288,267,845.67, representing a growth of approximately 68.3% year-over-year[197]. - Owner's equity totaled ¥828,736,823.78, compared to ¥740,870,281.75, reflecting an increase of about 11.8%[197]. Shareholder Information - The total number of shares before the recent change was 144,789,501, with a total of 47,841,493 restricted shares, accounting for 33.04% of the total[149]. - The largest shareholder, Yang Minmin, holds 31,774,630 shares, representing 21.95% of the total shares[153]. - The company reported a decrease of 926,250 restricted shares due to the unlocking of shares held by former director Wu Xihan[152]. - The total number of shareholders at the end of the reporting period was 8,968[153]. Environmental Compliance - Nanjing Yaoshi Technology reported a total annual pollutant discharge of 7.03 tons for COD and 0.44 tons for NH3-N from its new drug intermediate R&D project[137]. - The company has established wastewater discharge standards of COD ≤ 500 mg/L and NH3-N ≤ 45 mg/L, in compliance with national regulations[137]. - The company has implemented emergency response plans for environmental incidents, which have been reviewed by experts and filed with the environmental protection bureau[140].

Financial Performance - Total revenue for Q1 2020 was ¥170,584,228.47, an increase of 12.30% compared to ¥151,907,064.37 in the same period last year[9] - Net profit attributable to shareholders was ¥28,212,630.51, a decrease of 15.81% from ¥33,511,621.18 year-on-year[9] - Net profit excluding non-recurring gains and losses was ¥25,636,226.95, down 18.80% from ¥31,571,442.36 in the previous year[9] - Basic earnings per share decreased by 17.39% to ¥0.19 from ¥0.23 in the same period last year[9] - Diluted earnings per share also decreased by 17.39% to ¥0.19 from ¥0.23 year-on-year[9] - The company reported steady growth in operating income and net profit, with Q1 2020 net profit attributable to shareholders at ¥3,752.31 million[35] - The total profit for the current period is CNY 31,769,680.24, compared to CNY 38,403,886.52 in the previous period, showing a decline in profitability[72] - The total comprehensive income amounted to CNY 25,545,921.17, a decrease from CNY 30,544,833.40 in the previous period, reflecting a decline of approximately 16.4%[82] Cash Flow and Liquidity - Net cash flow from operating activities increased by 152.23% to ¥52,891,683.93 from ¥20,969,362.34 in the same period last year[9] - Cash inflow from operating activities was CNY 216,601,273.69, up from CNY 135,825,540.44, representing an increase of about 59.5%[83] - Cash inflow from investment activities totaled CNY 181,572,283.29, a substantial increase from CNY 83,346,935.39, marking an increase of approximately 117.5%[86] - Cash inflow from financing activities was CNY 95,000,000.00, compared to CNY 30,011,636.50, reflecting an increase of about 216.5%[89] - The net increase in cash and cash equivalents was CNY 71,175,618.31, contrasting with a decrease of CNY -142,532,548.31 in the prior period[89] - The ending balance of cash and cash equivalents was CNY 215,753,157.65, up from CNY 121,932,411.46, indicating a growth of approximately 77%[89] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,159,915,572.92, up 12.71% from ¥1,029,138,127.42 at the end of the previous year[9] - Total assets amounted to CNY 1,191,588,569.14, an increase from CNY 1,024,831,085.14 year-over-year[66] - Total liabilities increased to CNY 412,169,828.97 from CNY 282,083,453.87, reflecting a significant rise of approximately 46.1%[66] - Owner's equity totaled CNY 779,418,740.17, up from CNY 742,747,631.27, representing an increase of about 4.9%[66] - The company has not experienced any significant changes in project feasibility[42] Investments and R&D - The company plans to enhance its product technology and R&D capabilities to strengthen its competitive position in the global pharmaceutical market[30] - Research and development expenses increased to CNY 16,985,603.04 from CNY 14,524,273.07, indicating a focus on innovation and product development[76] - The company aims to capitalize on the rapid growth of the pharmaceutical market in emerging economies to improve overall competitiveness and profitability[30] Supplier and Customer Dynamics - The total procurement amount from the top five suppliers was ¥72,498,033.33, accounting for 61.78% of the total procurement, compared to ¥16,004,849.62 and 38.85% in the same period last year[31] - The total sales amount from the top five customers was ¥89,339,329.45, representing 52.37% of total operating income, up from ¥74,535,360.91 and 49.07% in the same period last year[32] - The company has not experienced significant reliance on a single supplier or customer, with changes in the top five suppliers and customers being normal and not impacting operations[31][32] Strategic Plans and Market Position - The company plans to raise up to ¥65,000.00 million through a non-public stock issuance to supplement working capital and repay bank loans[36] - The company aims to expand sales channels and enhance cooperation with clients to mitigate risks associated with slower drug development progress by clients[35] - The company is focused on maintaining its competitive edge through increased R&D investment and cost optimization[35] Compliance and Governance - There are no reported violations regarding external guarantees during the reporting period[43] - The company has not made any adjustments to its annual operating plan despite the impact of COVID-19, continuing to leverage its technological advantages[33] - The company has not utilized any idle raised funds for supplementary working capital[42]

Financial Performance - The company's operating revenue for 2019 was ¥662,230,933.19, representing a 38.47% increase compared to ¥478,254,313.96 in 2018[22] - The net profit attributable to shareholders for 2019 was ¥152,068,782.22, a 14.03% increase from ¥133,363,374.84 in 2018[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥136,914,624.38, up 15.64% from ¥118,401,299.43 in 2018[22] - The basic earnings per share for 2019 were ¥1.06, reflecting a 13.98% increase from ¥0.93 in 2018[22] - The diluted earnings per share also stood at ¥1.06, up 13.98% from ¥0.93 in 2018[22] - The gross profit margin for the year was 51.59%[35] - The company reported quarterly operating revenues of 151.91 million yuan, 138.57 million yuan, 173.72 million yuan, and 198.03 million yuan for Q1 to Q4 respectively[23] - The net profit attributable to shareholders for Q1 to Q4 was 33.51 million yuan, 35.76 million yuan, 48.16 million yuan, and 34.64 million yuan respectively[23] - The company’s operating costs for raw materials amounted to ¥242,021,749.65, which is 75.50% of total operating costs, reflecting a year-on-year increase of 79.25%[67] - The total sales volume increased by 82.20% year-on-year, reaching 41,418.55 kg, while production volume rose by 106.35% to 57,942.43 kg[66] Cash Flow and Investments - The net cash flow from operating activities decreased by 20.68% to ¥127,044,730.52 from ¥160,161,084.59 in 2018[22] - The net cash flow from operating activities for the year was 69.49 million yuan[26] - Total cash inflow from investment activities increased by 29.52% to ¥973,239,288.89, while cash outflow from investment activities surged by 61.15% to ¥1,273,907,304.84, resulting in a net cash flow from investment activities of -¥300,668,015.95, a decrease of 669.03%[81] - Cash inflow from financing activities rose significantly by 288.09% to ¥114,582,203.66, while cash outflow increased by 29.64% to ¥63,485,280.80, leading to a net cash flow from financing activities of ¥51,096,922.86, an increase of 362.78%[81] - The net increase in cash and cash equivalents was -¥119,887,420.43, a decrease of 212.15% compared to the previous year[81] - The total investment amount for the reporting period was ¥219,953,800.00, a substantial increase of 160.92% compared to the previous year[90] Assets and Liabilities - The total assets at the end of 2019 were ¥1,029,138,127.42, a 35.21% increase from ¥761,161,443.52 at the end of 2018[22] - The net assets attributable to shareholders increased by 23.53% to ¥740,866,683.70 from ¥599,729,719.40 at the end of 2018[22] - Accounts receivable rose by 125.84%, attributed to increased sales revenue and a growing customer base[38] - The total amount committed for investment projects is 18,272.4 million yuan, with 10,982.38 million yuan invested during the reporting period[98] - Inventory rose to ¥206,915,519.30, making up 20.11% of total assets, reflecting the expansion of business operations[85] Research and Development - The company has developed a library of thousands of unique drug molecular building blocks for small molecule drug research[35] - The company reported a total R&D expenditure of ¥69,221,259.54, representing 10.45% of total sales revenue, with a significant increase in R&D personnel from 113 to 191[75][76] - The company plans to enhance its R&D investment to develop innovative drug molecular building blocks, aiming to support drug discovery processes more efficiently[114] - The company has established a drug molecular building block library platform to enhance its production capabilities for key intermediates[114] Market and Business Development - The company is focused on expanding its business both domestically and internationally, enhancing its brand presence[35] - Domestic revenue reached ¥180,000,957.93, accounting for 27.18% of total revenue, while international revenue was ¥482,229,975.26, making up 72.82%[63] - The company has established long-term partnerships with major pharmaceutical giants, enhancing its competitive advantage in the industry[47] - The company actively participated in industry conferences, enhancing its brand image and technical reputation in the pharmaceutical R&D sector[55] Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥1.5 per 10 shares to all shareholders[6] - The cash dividend per 10 shares is RMB 1.5, with a total share base of 144,789,501 shares[124] - The company's cash dividend payout ratio for 2019 is 14.28% of the net profit attributable to ordinary shareholders[129] - The total distributable profit for the reporting period was RMB 286,333,663.19[124] - The company has a clear and transparent profit distribution policy, ensuring the protection of minority shareholders' rights[123] Compliance and Governance - The company has ensured strict compliance with all share transfer commitments as of the report date[149] - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of the initial public offering[140] - The company guarantees that any income obtained from violating share transfer commitments will be returned to the issuer within 20 days of receiving a notice from the board[141] - The company has established a long-term commitment to comply with all relevant laws and regulations regarding related transactions and profit distribution[176] Risks and Challenges - The company has identified risks related to performance growth slowdown, with strategies to expand sales channels and strengthen customer relationships to mitigate this risk[114] - The company is also facing risks of declining gross margins due to increased competition, with plans to maintain its competitive edge through R&D and cost optimization[114] Employee and Incentive Programs - The company granted 1,789,500 restricted shares to 72 incentive targets, impacting profits by -11,125,187.73 CNY during the reporting period[195] - The company has adhered to all commitments regarding the issuance of restricted shares and has not provided any financial assistance to incentive targets[195]

Financial Performance - The company's operating revenue for 2019 was ¥662,230,933.19, representing a 38.47% increase compared to ¥478,254,313.96 in 2018[22] - The net profit attributable to shareholders for 2019 was ¥152,068,782.22, an increase of 14.03% from ¥133,363,374.84 in 2018[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥136,914,624.38, up 15.64% from ¥118,401,299.43 in 2018[22] - The total assets at the end of 2019 were ¥1,029,138,127.42, a 35.21% increase from ¥761,161,443.52 at the end of 2018[22] - The net assets attributable to shareholders increased by 23.53% to ¥740,866,683.70 from ¥599,729,719.40 in 2018[22] - The basic earnings per share for 2019 were ¥1.06, a 13.98% increase from ¥0.93 in 2018[22] - The diluted earnings per share also stood at ¥1.06, reflecting the same growth of 13.98% from ¥0.93 in 2018[22] - The weighted average return on equity was 22.94%, slightly down from 22.97% in 2018[22] - The gross profit margin for the company was 51.59% in 2019[36] - The company reported a net cash flow from operating activities of 20.97 million yuan[28] Cash Flow and Investments - The net cash flow from operating activities decreased by 20.68% to ¥127,044,730.52 from ¥160,161,084.59 in 2018[22] - Cash and cash equivalents decreased by 38.45%, mainly due to payments for capital increases and acquisitions[40] - Total cash inflow from investment activities rose by 29.52% to ¥973,239,288.89, while cash outflow surged by 61.15% to ¥1,273,907,304.84, resulting in a net cash outflow of ¥300,668,015.95[86] - The company reported a significant increase in financing cash inflow by 288.09% to ¥114,582,203.66, attributed to employee stock option subscriptions and increased short-term borrowings[86] - The investment amount for the reporting period reached ¥219,953,800, a significant increase of 160.92% compared to ¥84,298,561 in the same period last year[96] Research and Development - The company has developed a library of thousands of unique drug molecular building blocks for small molecule drug research[36] - The company employs 191 R&D personnel, representing 29.25% of its total workforce, with a strong educational background in relevant fields[47] - R&D expenses amounted to ¥69,221,259.54, representing 10.45% of total sales revenue, reflecting a 56.08% increase year-on-year[79] - The number of R&D personnel increased to 191 in 2019, accounting for 29.29% of the total workforce, up from 22.07% in 2018[80] - The company plans to enhance its R&D investment to maintain its competitive edge in technology and products, aiming for innovative drug molecule building blocks[1] Market Position and Strategy - The company is focused on expanding its business both domestically and internationally, enhancing its brand presence[36] - The company has established long-term partnerships with major pharmaceutical firms, including Novartis and Merck, which strengthens its competitive advantage in the industry[50] - The company’s business model emphasizes customer needs, providing tailored solutions to accelerate drug development[35] - The company aims to establish a high-level one-stop CDMO service platform for biopharmaceuticals, enhancing its capabilities in drug development and commercialization[1] - The company is positioned to support clients through various stages of drug development, from discovery to commercialization[34] Shareholder Returns and Dividends - The company plans to distribute a cash dividend of ¥1.5 per 10 shares to all shareholders, based on a total of 144,789,501 shares[6] - The cash dividend for the year was CNY 1.5 per 10 shares, with a total cash dividend amounting to CNY 21,718,425.15, representing 100% of the total profit distribution[1][3] - The company has not proposed any cash dividends for the current reporting period despite having positive profits[133] - The total cash dividends distributed over the past three years were RMB 58,385,091.15, with a decreasing trend in the payout ratio[135] Compliance and Governance - The company has confirmed that there are no undisclosed related party transactions as per legal requirements[181] - The company committed to maintaining independence in operations, ensuring no illegal occupation of funds or assets[181] - The company has adhered to its commitments regarding profit distribution policies and plans as approved by the shareholders' meeting[186] - The company has taken necessary measures to ensure compliance with the profit distribution policies and plans[186] - The company has maintained compliance with all regulatory commitments regarding share transfers and holdings[136] Operational Efficiency - The company will continue to optimize its internal management systems to improve operational efficiency and foster a positive corporate culture[1] - The company has established a quality management system compliant with GB/T19001-2016 and ISO9001:2015 standards for drug molecular fragments and intermediates[53] - The company has committed to a lock-up period of 36 months for shares acquired through a private placement, starting from September 8, 2016, during which no transfers or management delegation of these shares is allowed[145] Risks and Challenges - The company faces risks related to performance growth slowdown, with potential impacts from clients' R&D investment reductions[1] - The company emphasizes environmental protection and safety production, increasing investments in environmental facilities to mitigate risks[1]

Financial Performance - Operating revenue for the period was ¥173,722,435.32, representing a year-on-year growth of 35.38%[9] - Net profit attributable to shareholders was ¥48,160,653.29, reflecting a 17.87% increase year-on-year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥45,493,506.00, up 20.66% from the same period last year[9] - Basic earnings per share for the period was ¥0.3368, an increase of 17.89% compared to the previous year[9] - The company reported a total comprehensive income of ¥47,637,322.95 for the current period, compared to ¥42,316,316.42 in the previous period, reflecting a growth of 12.5%[62] - The net profit for the year-to-date period was ¥117,431,441.71, compared to ¥95,150,610.68 in the previous year, reflecting an increase of about 23.3%[76] - The net profit for the current period was ¥40,239,454.10, compared to ¥39,782,352.79 in the previous period, reflecting an increase of approximately 1.15%[66] Assets and Liabilities - Total assets at the end of the reporting period reached ¥935,516,845.04, an increase of 22.91% compared to the end of the previous year[9] - Current assets totaled approximately ¥510.69 million, slightly up from ¥509.13 million year-over-year, indicating a marginal increase of 0.31%[35] - Non-current assets reached ¥424.83 million, a substantial increase of 68.49% from ¥252.03 million year-over-year[38] - Total liabilities increased to ¥241.16 million from ¥161.43 million, showing a rise of 49.38%[41] - Owner's equity rose to ¥694.36 million from ¥599.73 million, indicating an increase of 15.77%[44] - Total liabilities increased to ¥281,534,980.22 from ¥157,522,965.28, reflecting a growth of 78.5%[54] - Total assets reached ¥993,975,663.60, up from ¥786,325,024.42, representing a growth of 26.4%[54] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥57,554,507.35, down 35.44% compared to the previous year[9] - Cash flow from operating activities generated ¥57,554,507.35, down 35.5% from ¥89,145,846.49 in the previous period[90] - The net cash outflow from investment activities was -275,005,154.41, worsening from -125,156,940.90 in the previous period[99] - The net cash flow from financing activities was 35,866,149.80, compared to a negative flow of -19,682,258.45 in the previous period, indicating a significant improvement[102] - The total cash and cash equivalents at the end of the period stood at 61,291,934.86, a decrease from 63,811,086.80 in the previous period[102] Research and Development - R&D expenses rose by 76.00% to ¥50,094,028.43, indicating a continued commitment to enhancing research capabilities[26] - Research and development expenses for the current period were ¥20,343,873.60, which is a significant increase from ¥10,166,612.14 in the previous period, indicating a focus on innovation[55] - Research and development expenses increased significantly to ¥17,197,490.24 from ¥8,089,844.08, marking a rise of about 112.5%[66] - The company’s R&D expenses for the year-to-date period were ¥50,094,028.43, significantly higher than ¥28,463,244.49 in the previous year, indicating an increase of approximately 76%[73] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,318[13] - Major shareholder Yang Minmin holds 22.22% of the shares, totaling 31,774,630 shares, with 3,000,000 shares pledged[13] Investment Activities - The company reported an investment loss of ¥861,419.62, a decline of 117.34% due to losses from Huishi[26] - Cash inflow from investment activities totaled ¥694,516,374.45, compared to ¥504,966,955.58, showing a 37.5% increase[90] - The company invested 877,434,000.00 in fixed assets, intangible assets, and other long-term assets, compared to 616,522,500.00 in the previous period, reflecting a 42.3% increase[99] Future Plans - The company has plans for market expansion and new product development, focusing on enhancing its competitive edge in the pharmaceutical sector[40] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[86]

Financial Performance - Total revenue for the first half of 2019 reached ¥290,478,611.12, representing a 37.80% increase compared to ¥210,798,266.43 in the same period last year[30]. - Net profit attributable to shareholders was ¥69,267,874.80, up 30.31% from ¥53,156,706.58 year-on-year[30]. - Net profit after deducting non-recurring gains and losses was ¥65,316,768.31, reflecting a 35.28% increase from ¥48,282,438.20 in the previous year[30]. - Basic earnings per share increased to ¥0.48, a rise of 29.73% compared to ¥0.37 in the same period last year[30]. - The company reported a total non-operating income of RMB 3,951,106.49, after accounting for tax impacts of RMB 737,168.38[37]. - The company achieved operating revenue of ¥290,478,611.12, an increase of 37.8% compared to the same period last year[47]. - The net profit attributable to shareholders reached ¥69,267,874.8, reflecting a growth of 30.31% year-on-year[47]. - The company reported a 30.88% increase in operating profit, amounting to RMB 76,258,144.53[55]. - The total profit for the first half of 2019 was RMB 79,248,044.64, marking a 30.07% increase year-on-year[55]. - The comprehensive gross margin for the first half of 2019 was 56.35%, a decrease from 57.82% in 2018, indicating potential risks in maintaining competitive advantages in technology and products[100]. Assets and Liabilities - Total assets at the end of the reporting period were ¥871,177,313.49, marking a 14.45% increase from ¥761,161,443.52 at the end of the previous year[30]. - Net assets attributable to shareholders increased to ¥646,724,140.08, up 7.84% from ¥599,729,719.40 at the end of the previous year[30]. - The company's total equity increased to ¥672,201,229.28 in the first half of 2019, compared to ¥628,802,059.14 in the same period last year, reflecting a growth of 6.9%[194]. - Total liabilities amounted to CNY 224,453,173.41, up from CNY 161,431,724.12, indicating a growth of around 39.0%[184]. - Current liabilities increased to CNY 216,399,700.79 from CNY 152,898,616.66, which is an increase of about 41.5%[180]. - The company's equity attributable to shareholders reached CNY 646,724,140.08, compared to CNY 599,729,719.40, showing an increase of approximately 7.8%[184]. Cash Flow - The net cash flow from operating activities decreased significantly by 64.52% to ¥24,447,606.12 from ¥68,901,807.09 in the same period last year[30]. - The company's cash and cash equivalents decreased by 62.61%, primarily due to payments for capital increases and purchasing bank financial products[48]. - The net increase in cash and cash equivalents was RMB -167,956,844.31, a decline of 212.49% compared to RMB -53,748,026.50 in the previous year[60]. - The company reported a net cash outflow from investment activities of RMB 226,533,149.81, a 124.78% increase from RMB -100,780,201.00, primarily due to payments for investments[60]. - The company reported a decrease in cash and cash equivalents to CNY 88,133,306.63 from CNY 254,166,497.68, a decline of about 65.3%[185]. Research and Development - Research and development investment increased by 62.60% to RMB 29,750,154.83 from RMB 18,296,632.35, reflecting the company's commitment to technological innovation[60]. - The company designed over 4,000 molecular building blocks and synthesized more than 1,000 unique molecular building blocks in the first half of 2019[55]. - The company has established advanced technology platforms including continuous flow chemistry and enzyme catalysis to enhance production efficiency[55]. - The company emphasizes continuous R&D investment to maintain its competitive edge and optimize processes to reduce costs and ensure profitability[100]. Business Operations - The main business includes the design, synthesis, and sales of drug molecular building blocks, with a focus on key intermediates and related technical services[41]. - The company offers a variety of drug molecular building blocks, including aromatic heterocycles and saturated cyclic compounds, which are essential in new drug development[41]. - The business model emphasizes customer needs, providing solutions to enhance the efficiency and success rate of drug development projects[41]. - The company has established a complete procurement, R&D, production, testing, and sales system to meet customer demands independently[41]. - The company focuses on providing kilogram-scale drug molecular building blocks during the drug discovery phase and larger quantities during clinical trials and commercialization[41]. - The company has a library of over 10,000 drug molecular building blocks, ensuring high-quality sustainable supply[46]. - The company’s vertical integration in chemical services enhances long-term stable cooperation with global clients[46]. - The company is focused on vertical integration in chemical services, supporting drug development from molecular design to commercial production[55]. Risks and Challenges - The company faces risks including slowing performance growth and declining gross margins[7]. - The company plans to expand sales channels and enhance cooperation with clients to mitigate risks associated with slowing performance growth due to potential reductions in clients' R&D investments[100]. - The company has invested in environmental protection and safety production measures to address risks related to waste management and hazardous materials during the drug molecule block development process[100]. Shareholder Information - The total number of shares increased from 110,000,001 to 143,000,001 after a capital reserve conversion of 33,000,000 shares[135]. - The basic earnings per share for the first half of 2019 was 0.4844 CNY, compared to 0.9326 CNY for the full year of 2018[138]. - The net asset per share attributable to ordinary shareholders increased from 4.19 CNY in 2018 to 4.52 CNY in the first half of 2019[138]. - The proportion of limited shares decreased from 36.98% to 36.43% after the share conversion[135]. - The number of shareholders holding more than 5% of shares includes Yang Minmin with 22.22% and Nanjing Novicos with 7.39%[142]. - The company reported a decrease in the number of shares held by domestic natural persons from 26.97% to 26.42%[135]. - The company has not conducted any share repurchase transactions during the reporting period[138]. Regulatory and Compliance - The company reported no significant litigation or arbitration matters during the reporting period, reflecting a stable legal environment for operations[109]. - The company engaged in related party transactions amounting to 63.31 million CNY, which accounted for 23.00 million CNY of approved transaction amounts, ensuring compliance with market pricing principles[114]. - The company has not experienced any asset or equity acquisition or sale-related transactions during the reporting period, maintaining a stable asset structure[117]. - The company has not disclosed any other necessary information as required by regulatory authorities[138].

Financial Performance - Total revenue for Q1 2019 reached ¥151,907,064.37, representing a 53.07% increase compared to ¥99,240,994.02 in the same period last year[9] - Net profit attributable to shareholders was ¥33,511,621.18, up 66.88% from ¥20,081,573.12 year-on-year[9] - Net profit excluding non-recurring gains and losses was ¥31,571,442.36, reflecting a 74.13% increase from ¥18,131,000.87 in the previous year[9] - Basic earnings per share increased to ¥0.30, a rise of 66.67% compared to ¥0.18 in the same period last year[9] - The company achieved operating revenue of ¥151,907,064.37, representing a 53.07% increase compared to the same period last year[23] - The net profit attributable to shareholders reached ¥33,511,621.18, reflecting a growth of 66.88% year-on-year[26] - Operating profit for the current period was ¥36,379,180.16, representing a 47.9% increase from ¥24,597,607.62 in the previous period[73] - Net profit for the current period was ¥33,511,621.18, an increase of 58.0% compared to ¥21,201,725.34 in the same period last year[73] - The total comprehensive income for the current period was ¥33,521,275.10, up from ¥20,941,875.30 in the previous period, marking a 60.4% increase[77] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥814,259,073.33, a 6.98% increase from ¥761,161,443.52 at the end of the previous year[9] - Total liabilities increased to ¥181,008,078.88, up from ¥161,431,724.12, representing a growth of approximately 12.3% year-over-year[56] - The total owner's equity reached ¥633,250,994.45, an increase from ¥599,729,719.40, reflecting a growth of about 5.6%[59] - The total assets amounted to ¥829,463,417.32, compared to ¥786,325,024.42, indicating an increase of around 5.5%[68] - The total current liabilities increased to ¥162,922,155.75 from ¥150,103,596.25, reflecting a growth of about 8.5%[66] Cash Flow - The net cash flow from operating activities was ¥20,969,362.34, a decrease of 10.78% compared to ¥23,503,993.38 in the same period last year[9] - Cash flow from operating activities generated a net cash flow of CNY 20,969,362.34, down from CNY 23,503,993.38 in the prior period[88] - Cash inflow from operating activities totaled CNY 135,825,540.44, an increase from CNY 127,365,568.89 year-over-year[88] - Cash outflow from operating activities was CNY 114,856,178.10, compared to CNY 103,861,575.51 in the previous period[88] - Cash flow from investing activities resulted in a net outflow of CNY 187,361,305.64, worsening from a net outflow of CNY 48,319,698.52 in the prior period[91] - Cash flow from financing activities generated a net inflow of CNY 29,024,361.32, compared to a net outflow of CNY 5,015,969.26 in the prior period[91] Investments and Expenses - Research and development expenses rose by 61.20% to ¥14,524,273.07, indicating increased investment in enhancing competitiveness[23] - The company executed a capital increase in Zhejiang Huishi, resulting in a 61.23% increase in long-term equity investments to ¥127,689,097.45[23] - Financial expenses for the current period were ¥5,695,467.57, significantly higher than ¥1,056,891.84 in the prior period[70] - Investment income showed a loss of ¥4,026,388.51, compared to a gain of ¥1,320,794.52 in the previous period[70] Market Position and Strategy - The company has successfully completed tens of thousands of orders in the drug molecular building block R&D and production sector, becoming one of the main suppliers in the industry[29] - The company plans to continue enhancing its product technology, R&D capabilities, and marketing management to strengthen its competitive position in the global drug molecular building block industry[29] - The company has established a vertical integration service system for new drug development, enhancing business stickiness with clients[29] - The company does not rely excessively on any single supplier or customer, indicating a diversified client and supplier structure[30][29] - The company plans to continue its stable operational activities and maintain growth in net profit for the upcoming periods[26] Risks and Challenges - The company's comprehensive gross margin for Q1 2019 was 58.37%, showing a decline from previous years, indicating potential risks in maintaining competitive advantages[33] - The company is focused on addressing risks related to environmental protection and safety production as it expands its business scale[34] - The company will increase R&D investment to maintain its competitive edge and ensure profitability amid potential gross margin declines[34] Miscellaneous - There were no significant changes in the shareholding structure, with the top ten shareholders holding a total of 70.51% of the shares[12] - The annual business plan is being executed normally, with no adjustments planned for the year[32] - The first quarter report was not audited, which may affect the reliability of the financial data presented[109]

Financial Performance - The company's operating revenue for 2018 was CNY 478,254,313.96, representing a 75.02% increase compared to CNY 273,250,557.29 in 2017[23]. - The net profit attributable to shareholders for 2018 was CNY 133,363,374.84, a 98.52% increase from CNY 67,179,202.18 in 2017[23]. - The net profit after deducting non-recurring gains and losses was CNY 118,401,299.43, up 80.15% from CNY 65,722,112.60 in 2017[23]. - The net cash flow from operating activities reached CNY 160,161,084.59, a significant increase of 193.12% compared to CNY 54,639,657.83 in 2017[23]. - Basic earnings per share for 2018 were CNY 1.21, reflecting a 53.16% increase from CNY 0.79 in 2017[23]. - Total assets at the end of 2018 amounted to CNY 761,161,443.52, a 34.15% increase from CNY 567,395,667.52 at the end of 2017[23]. - The net assets attributable to shareholders at the end of 2018 were CNY 599,729,719.40, up 21.10% from CNY 495,255,420.67 at the end of 2017[23]. Market and Business Strategy - The company is focused on expanding its market presence and developing new products and technologies[7]. - The company aims to expand its market presence by offering a wide range of innovative chemical products and services in the pharmaceutical R&D sector[36]. - The company has established a diverse library of drug molecular building blocks, which aids pharmaceutical companies in rapidly obtaining candidate compounds for drug discovery[36]. - The business model focuses on enhancing customer efficiency and success rates in drug development through a comprehensive procurement, R&D, production, and sales system[38]. - The company actively participates in industry exhibitions to showcase its products and gather market demand information[44]. Research and Development - The company designed over 7,000 unique molecular building blocks and developed nearly 2,000 distinctive molecular blocks in 2018[43]. - The company has developed a library of over 50,000 unique molecular building blocks for small molecule drug research[50]. - The company has strengthened its research and development investments in new technologies, successfully applying continuous flow chemistry in various complex reactions[44]. - Research and development expenses amounted to ¥44,350,189.21, representing 9.27% of total sales revenue, an increase from 9.05% in 2017[80]. Risks and Challenges - The company faces risks including slowing performance growth and declining gross margins, which investors should be aware of[7]. - The company aims to expand its sales channels and strengthen cooperation with clients to mitigate risks associated with potential slowdowns in drug development investments[116]. - The company faces risks related to environmental protection and safety production, which it addresses by investing in environmental facilities and improving management levels[116]. Investment and Acquisitions - The company acquired Zhejiang Boteng Pharmaceutical Co., Ltd., enhancing its commercial production capacity for drug molecular building blocks and key intermediates[53]. - The company completed the acquisition of Nanjing Annakang Biotechnology Co., Ltd. in December, but it did not impact the performance for the reporting period[111]. - The company acquired a 32.5% stake in Zhejiang Huishi Pharmaceutical Co., Ltd. for RMB 85,750,000, with a reported investment loss of RMB 6,551,889.00[92]. Profit Distribution - The board approved a profit distribution plan, proposing a cash dividend of CNY 2.00 per 10 shares[7]. - The cash dividend represents 16.50% of the net profit attributable to ordinary shareholders, which is RMB 133,363,374.84[126]. - The total distributable profit for the year is RMB 179,941,343.31, with the cash dividend accounting for 100% of the profit distribution[126]. Compliance and Governance - The company has not experienced any significant changes in the feasibility of the committed investment projects[102]. - The company has committed to maintaining operational independence from its actual controllers and related parties in terms of personnel, finance, and business operations[163]. - The company reported a commitment to avoid any undisclosed related-party transactions, ensuring compliance with legal regulations and corporate governance standards[160]. Related Party Transactions - The company reported a total of 2,400,000 RMB for related party transactions with Zhejiang Huishi Pharmaceutical, which accounted for 435.39% of similar transaction amounts[184]. - The company’s related party transactions did not have a significant adverse impact on its financial condition or operating results[195]. - The company has established fair pricing principles for related party transactions to ensure transparency[184].